In August 2023, the professional team from VCRO assisted the client in submitting the clinical trial application of their small molecule for the use of boron neutron capture therapy (BNCT) in the treatment of recurrent glioblastoma multiforme (rGBM). The team successfully obtained TFDA approval to proceed with Phase III clinical trials. We successfully supported our clients in smoothly advancing to the Phase III clinical trial stage. VCRO is here to accompany you through every stage of the clinical trial process.
